An expert panel of the country's central drug authority on Wednesday recommended against granting permission to the Serum Institute of India (SII) to conduct the phase 2/3 trial of COVID-19 vaccine Covovax on children aged two to 17 years, sources said.from IndiaTV India: Google News Feed https://ift.tt/3jvK48Z
Post a Comment